IMBiotechnologies Ltd. today announced that an oral presentation regarding the use of its lead product, *Occlusin® 500 Embolization Microspheres (Occlusin 500), in benign prostatic hypertrophy (BPH) patients will be presented at the 2018 Cardiovascular and Interventional Radiological Society of Europe (CIRSE) annual meeting. Dr. Richard Owen, lead investigator of the clinical study conducted at the University of Alberta Hospital, will be presenting qualitative data assessing prostate tissue and Occlusin 500 using ultrasound in patients after prostatic artery embolization. The presentation entitled “Ultrasound detection of a biodegradable embolic microsphere after prostatic artery embolization” and will be given by Dr. Owen on Saturday, September 22nd.
*Occlusin 500 is a first-in-class biodegradable embolic agent that is detectable by ultrasound. It is a class II medical device cleared in the USA for the treatment of unresectable/inoperable hypervascularized tumors. IMBiotechnologies is currently seeking Health Canada approval for Occlusin 500.